XML 211 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 16,209,000 $ 22,593,000
Marketable securities 15,036,000 27,942,000
Accounts receivable 900,000 0
Prepaid and other current assets 2,433,000 3,389,000
Total current assets 34,578,000 53,924,000
Property and equipment, net 72,000 175,000
Acquired license-intangible, net 192,000 263,000
Other assets 160,000 332,000
Total assets 35,002,000 54,694,000
Liabilities    
Accounts payable 1,284,000 2,421,000
Accrued liabilities 4,329,000 4,169,000
Total current liabilities 5,613,000 6,590,000
Other long-term liabilities 72,000 210,000
Total liabilities 5,685,000 6,800,000
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,409,582 and 8,150,635 shares, at December 31, 2024 and December 31, 2023, respectively; and outstanding, 8,408,844 and 8,149,897 shares, at December 31, 2024 and December 31, 2023, respectively 8,000 8,000
Additional paid-in capital 578,418,000 576,971,000
Treasury stock, at cost; 738 shares at December 31, 2024 and December 31, 2023 respectively (708,000) (708,000)
Accumulated deficit (548,066,000) (528,081,000)
Accumulated other comprehensive loss (81,000) (42,000)
Total Lisata Therapeutics, Inc. stockholders' equity 29,571,000 48,148,000
Non-controlling interests (254,000) (254,000)
Total equity 29,317,000 47,894,000
Total liabilities, non-controlling interests and stockholders' equity $ 35,002,000 $ 54,694,000